- Home
- WMB vs ZTS Comparison
WMB vs ZTS Comparison
Compare WMB & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WMB | ZTS |
|---|---|---|
| Founded | 1908 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.7B | 53.9B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | WMB | ZTS |
|---|---|---|
| Price | $62.98 | $125.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 11 |
| Target Price | $67.67 | ★ $174.60 |
| AVG Volume (30 Days) | ★ 6.4M | 4.7M |
| Earning Date | 02-11-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.25% | 1.72% |
| EPS Growth | N/A | ★ 11.64 |
| EPS | 1.94 | ★ 5.94 |
| Revenue | ★ $11,582,000,000.00 | $9,397,000,000.00 |
| Revenue This Year | $11.02 | $3.04 |
| Revenue Next Year | $5.29 | $4.96 |
| P/E Ratio | $31.72 | ★ $20.76 |
| Revenue Growth | ★ 11.73 | 2.68 |
| 52 Week Low | $51.58 | $115.25 |
| 52 Week High | $65.55 | $177.40 |
Technical Indicators
Market Signals| Indicator | WMB | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 50.30 |
| Support Level | $60.16 | $121.65 |
| Resistance Level | $61.37 | $126.50 |
| Average True Range (ATR) | 1.40 | 2.99 |
| MACD | 0.25 | -0.22 |
| Stochastic Oscillator | 98.68 | 37.97 |
Price Performance
Historical ComparisonAbout WMB Williams Companies Inc. (The)
Williams Companies is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.